Back to Search
Start Over
Lilly, AstraZeneca drop BACE inhibitor.
- Source :
-
C&EN Global Enterprise . 6/18/2018, Vol. 96 Issue 25, p15-15. 1/5p. - Publication Year :
- 2018
-
Abstract
- The article reports that pharmaceutical companies Eli Lilly & Co. and AstraZeneca are closing down Phase III studies of the Alzheimer's treatment lanabecestat, an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor as two trials showed its unlikeliness to slow down patients' cognitive decline.
- Subjects :
- *ENZYME inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 24747408
- Volume :
- 96
- Issue :
- 25
- Database :
- Academic Search Index
- Journal :
- C&EN Global Enterprise
- Publication Type :
- Periodical
- Accession number :
- 130347708
- Full Text :
- https://doi.org/10.1021/cen-09625-buscon15